OptimizeRx (NASDAQ:OPRX) Receives New Coverage from Analysts at JMP Securities

Investment analysts at JMP Securities started coverage on shares of OptimizeRx (NASDAQ:OPRX - Get Free Report) in a report released on Thursday, Marketbeat Ratings reports. The firm set a "mkt outperform" rating and a $15.00 price target on the stock. JMP Securities' target price points to a potential upside of 33.81% from the company's current price.

A number of other equities analysts also recently weighed in on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $17.00 price target on shares of OptimizeRx in a research note on Monday. Stifel Nicolaus reaffirmed a "buy" rating and issued a $13.00 price target on shares of OptimizeRx in a research note on Monday. Finally, Barclays initiated coverage on shares of OptimizeRx in a research note on Wednesday, January 3rd. They issued an "equal weight" rating and a $15.00 price target on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, OptimizeRx presently has an average rating of "Moderate Buy" and a consensus price target of $15.86.

OptimizeRx Trading Up 0.4 %

NASDAQ:OPRX traded up $0.04 during trading hours on Thursday, hitting $11.21. 129,262 shares of the stock traded hands, compared to its average volume of 120,953. OptimizeRx has a fifty-two week low of $6.92 and a fifty-two week high of $16.65. The firm has a market cap of $203.46 million, a price-to-earnings ratio of -14.01 and a beta of 0.98. The firm has a 50 day moving average price of $14.19 and a 200 day moving average price of $11.74.

Insider Buying and Selling

In related news, General Counsel Marion Odence-Ford sold 4,000 shares of the company's stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $15.19, for a total value of $60,760.00. Following the completion of the sale, the general counsel now directly owns 11,114 shares in the company, valued at $168,821.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On OptimizeRx

Hedge funds have recently bought and sold shares of the company. Kennedy Capital Management LLC bought a new stake in shares of OptimizeRx in the third quarter valued at about $4,323,000. AWM Investment Company Inc. lifted its stake in shares of OptimizeRx by 75.8% in the third quarter. AWM Investment Company Inc. now owns 782,571 shares of the company's stock valued at $6,088,000 after buying an additional 337,303 shares during the period. Wasatch Advisors LP lifted its stake in shares of OptimizeRx by 153.6% in the first quarter. Wasatch Advisors LP now owns 469,201 shares of the company's stock valued at $6,864,000 after buying an additional 284,152 shares during the period. Two Sigma Advisers LP lifted its stake in shares of OptimizeRx by 294.2% in the third quarter. Two Sigma Advisers LP now owns 317,700 shares of the company's stock valued at $4,708,000 after buying an additional 237,100 shares during the period. Finally, Two Sigma Investments LP lifted its stake in shares of OptimizeRx by 821.9% in the third quarter. Two Sigma Investments LP now owns 231,409 shares of the company's stock valued at $3,429,000 after buying an additional 206,308 shares during the period. 76.47% of the stock is currently owned by institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.